ALBERTDAVD · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 32/100 — Quality 31 · Momentum 34
| Share price | ₹898.60 |
| Market cap | ₹400 Cr |
| P/B ratio | 1.0 |
| ROE | -0.6% |
| ROCE | 0.8% |
| Dividend yield | 0.71% |
| Book value | ₹686.10 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹329 Cr | ₹-1 Cr | 0.0% |
| 2025 | ₹343 Cr | ₹17 Cr | -0.8% |
| 2024 | ₹360 Cr | ₹75 Cr | 11.4% |
| 2023 | ₹340 Cr | ₹36 Cr | 10.7% |
| 2022 | — | — | — |
Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs in India and internationally. It offers formulations for parenterals, oral/enterals, topical agents, aerosol, gynecology therapy, orthopedic, and vision care products. Albert David Limited was incorporated in 1938 and is headquartered in Kolkata, India.